# Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.

> **NCT05835726** · — · COMPLETED · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 188 (actual)

## Conditions studied

- Multiple Myeloma
- Daratumumab
- Autologous Stem Cell Transplantation
- Leukapheresis

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT05835726
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835726, "Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05835726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*